GlassScriptPhysician profile
Brad A Mcintosh
NPI 1659373819
$11,248.18
in general payments reported to CMS, 2019-2025
54 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,135 · 2020: $741 · 2021: $2,404 · 2022: $1,817 · 2023: $1,958 · 2024: $1,681 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,101 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,100.74 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,909.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,521.03 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $921.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $836.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $818.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $726.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $647.84 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $329.75 | 2019-2023 | Xarelto |
| Abbott Laboratories | $312.13 | 2023-2025 | Freestyle Libre 3, Freestyle Copilot |
| Merck Sharp & Dohme LLC | $253.35 | 2019-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.84 | 2021-2025 | Jardiance |
| Mayne Pharma Commercial LLC | $223.07 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.46 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $179.85 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $176.02 | 2024-2025 | Voquezna |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Mcintosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.